Supriya Lifescience: PAT growth of 59% & Revenue growth of 29% in 9M-24 at PE of 24
www.moneymuscle.in
SUPRIYA is on track to delivering revenue of Rs 1,000 cr by FY27 while maintaining EBITDA margin of 28-30%. The revenue CAGR of 20%+ for FY23-27 could provide opportunity for the stock.
Supriya Lifescience: PAT growth of 59% & Revenue growth of 29% in 9M-24 at PE of 24
Supriya Lifescience: PAT growth of 59% …
Supriya Lifescience: PAT growth of 59% & Revenue growth of 29% in 9M-24 at PE of 24
SUPRIYA is on track to delivering revenue of Rs 1,000 cr by FY27 while maintaining EBITDA margin of 28-30%. The revenue CAGR of 20%+ for FY23-27 could provide opportunity for the stock.